Evofem Biosciences Inc

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Aug. 21, 2020 /PRNewswire/ -- Evofem Biosciences, Inc.

Evofem Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Investors need to pay close attention to Evofem Biosciences (EVFM) stock based on the movements in the options market lately.

Do Options Traders Know Something About Evofem Biosciences (EVFM) Stock We Don't?

Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q2 2020 Results - Earnings Call Transcript

SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Evofem Biosciences, Inc.

Evofem Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update

SAN DIEGO, July 1, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company, today announced that it has issued a letter to its stockholders providing an update on recent events and outlook for the remainder of 2020 and early 2021. The...

Evofem Biosciences Issues Mid-Year 2020 Letter to Stockholders

Are Options Traders Betting on a Big Move in Evofem Biosciences (EVFM) Stock?

Evofem Biosciences (EVFM) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

Evofem Biosciences (EVFM) Looks Good: Stock Adds 10.1% in Session

Evofem Biosciences Inc (NASDAQ: EVFM) shares are trading higher on Monday after Piper Sandler initiated coverage on the company's stock with an Outperform rating and announced an $11 price target.

Why Evofem Biosciences Is Trading Higher Today

The company announced the pricing of a public offering of common stock.

Why Evofem Biosciences Is Down Today

SAN DIEGO, June 2, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today announced the pricing of an...

Evofem Announces Pricing of Approximately $100 Million Public Offering of Common Stock

SAN DIEGO, June 2, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today announced that it intends...

Evofem Announces Proposed Public Offering of Common Stock

Here's why a company making a novel contraceptive will be well awarded for tackling an old problem with a new twist.

Finally, Some Good News for Evofem Biosciences

Evofem Biosciences Inc (NASDAQ: EVFM) shares gap-opened higher Tuesday morning after a binary event panned out in the company's favor.

Why Shares Of Women's Health-Focused Biopharma Evofem Are Rallying

Evofem Biosciences scored a major regulatory win last Friday.

Why Evofem Biosciences Stock Is on Fire Today

Evofem Biosciences: FDA Approval Beginning Of Strong 2020

Evofem Biosciences Inc. EVFM, +3.31% stock rallied in the extended session Friday after the biotech company said the Food and Drug Administration approved its birth-control gel.

Evofem stock rallies as FDA approves birth-control gel

SAN DIEGO, May 22, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that the U.S. Food and Drug Administration (FDA) has approved Phexxi™ (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive...

U.S. FDA Approves Evofem Biosciences' Phexxi™ (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy

INCLINE VILLAGE, Nev., May 21, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that it has completed its previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem") (Nasdaq:...

PDL BioPharma Completes Distribution of Evofem Biosciences Common Stock to PDL Stockholders

INCLINE VILLAGE, Nev., May 18, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the final distribution ratio for the previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem")...

PDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL Stockholders

Evofem Biosciences Inc. (EVFM) CEO Saundra Pelletier on Q1 2020 Results - Earnings Call Transcript

This Small Biotech Is About To Take Off

Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q4 2019 Results - Earnings Call Transcript

BeyondSpring

Earthstone Energy

Misonix

Playa Hotels & Resorts

Sequans Communications

No matter which strategy is employed or what types of stocks are sought after, investors want to see returns. 
The post 7 ‘Strong Buy’ Stocks With Over 50% Upside Potential appeared first on InvestorPlace.

7 ‘Strong Buy’ Stocks With Over 50% Upside Potential

Shares jump after the company reports upbeat clinical results. Here are the must-know details.

Why Evofem Biosciences Is Soaring Today

Evofem Biosciences Inc. EVFM, +0.33% reported positive results in a mid-stage trial of a treatment for chlamydia and gonorrhea in women, sending its stock up 18% in premarket trade Monday.

News for Evofem Biosciences Inc Stock (EVFM)